SCHEMBL5762853

SCHEMBL5762853

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)Nc4ccccc4N4CCCCC4)cc3)ccc2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.51
MCOLN3 Q8TDD5 3/20 0.51
PKM P14618 2/20 0.51
DNMT1 P26358 1/20 0.43
CASP6 P55212 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 5/20 0.41
PRKDC P78527 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NAMPT P43490 3/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 2/20 0.39
ERAP1 Q9NZ08 1/20 0.39
CYP3A4 P08684 1/20 0.38
HSD17B10 Q99714 1/20 0.38
BRPF1 P55201 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5861640 0.83 MCOLN3 (0.51) L3MBTL1MCOLN3PKMDNMT1CASP6
SCHEMBL5758920 0.81 KMT2A (0.40) PKMTDP1ALDH1A1MEN1KMT2A
SCHEMBL5761750 0.81 KDM4E (0.46) PKMTDP1ALDH1A1MEN1KMT2A
SCHEMBL5762902 0.81 PKM (0.54) PKMALDH1A1MEN1KMT2ALMNA
SCHEMBL5759756 0.80 LMNA (0.51) PKMTDP1ALDH1A1MEN1KMT2A
SCHEMBL6106327 0.79 L3MBTL1 (0.50) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL6106621 0.79 L3MBTL1 (0.50) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL6106075 0.79 L3MBTL1 (0.50) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL5761962 0.78 KDM4E (0.46) PKMALDH1A1MEN1KMT2AGAA
SCHEMBL5860398 0.77 SLC40A1 (0.55) TDP1ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT L3MBTL1 4663/4885MCOLN3 2947/4885PKM 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.